Karyopharm Therapeutics Inc. (KPTI) |
|
3.49 0.17 (5.12%)
|
03-27 16:00 |
|
Open: |
3.28 |
Pre. Close: |
3.32 |
|
High:
|
3.55 |
Low:
|
3.2507 |
|
Volume:
|
1,680,784 |
Market Cap:
|
396(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:20:40 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 4.18  One year: 4.89 |
| Support: |
Support1: 3.12 Support2: 2.83 |
| Resistance: |
Resistance1: 3.58 Resistance2: 4.18 |
| Pivot: |
3.31 |
| Moving Average: |
MA(5): 3.34 MA(20): 3.26
MA(100): 3.74 MA(250): 4.77 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 67.7 %D(3): 62.7 |
| RSI: |
RSI(14): 56.5 |
| 52-week: |
High: 8.63 Low: 2.45 |
| Average Vol(K): |
3-Month: 2,684 (K) 10-Days: 2,854 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KPTI ] has closed below upper band by 27.3%. Bollinger Bands are 36.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.56 - 3.57 |
3.57 - 3.59 |
|
Low:
|
3.21 - 3.23 |
3.23 - 3.25 |
|
Close:
|
3.46 - 3.49 |
3.49 - 3.52 |
|
Company Description |
|
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. |
Headline News |
Mon, 27 Mar 2023
Karyopharm Therapeutics Inc. (KPTI) vs. Its Peers: A Comparison - The News Heater
Mon, 27 Mar 2023
Why Acquire Shares Of Karyopharm Therapeutics Inc. (KPTI)? - Marketing Sentinel
Sun, 26 Mar 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Holdings ... - MarketBeat
Sat, 18 Mar 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus ... - MarketBeat
Mon, 13 Mar 2023
Is Karyopharm Therapeutics Inc (KPTI) a Stock to Watch After Gaining 6.87% This Week? - InvestorsObserver
Thu, 09 Mar 2023
Have Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Insiders Been Selling Their Stock? - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
113 (M) |
| Shares Float |
72 (M) |
|
% Held by Insiders
|
6.2 (%) |
|
% Held by Institutions
|
72.6 (%) |
|
Shares Short
|
23,140 (K) |
|
Shares Short P.Month
|
20,910 (K) |
Stock Financials |
|
EPS
|
-2.73 |
|
EPS Est Next Qtl
|
-0.62 |
|
EPS Est This Year
|
-2.62 |
|
EPS Est Next Year
|
-2.31 |
|
Book Value (p.s.)
|
-0.53 |
|
Profit Margin (%)
|
-35.3 |
|
Operating Margin (%)
|
-20.7 |
|
Return on Assets (ttm)
|
-13.3 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
-4.1 |
|
Gross Profit (p.s.)
|
0.5 |
|
Sales Per Share
|
2.2 |
|
EBITDA (p.s.)
|
-0.45 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-97 (M) |
|
Levered Free Cash Flow
|
-56 (M) |
Stock Valuations |
|
PE Ratio
|
-1.29 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-6.59 |
|
Price to Sales
|
1.58 |
|
Price to Cash Flow
|
-4.07 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
